What is Lakefront Biotherapeutics NV Net Margin %?
Lakefront Biotherapeutics NVWBO:LKFT +0.79%60 Net Margin % is 223.61% as of Mar. 2026, which is 5895% above its 10-year median of 3.73. GuruFocus rates WBO:LKFT with a GF Score™ of 60/100 and a GF Value™ of €104.25 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 947 Biotechnology companies, Lakefront Biotherapeutics NV ranks better than 94.83% on this metric.
The historical rank and industry rank for Lakefront Biotherapeutics NV's Net Margin % or its related term are showing as below:
WBO:LKFT'
s Net Margin % Range Over the Past 10 Years
Min: -91.04 Med: 3.73 Max: 88.31
Current: 46.83
WBO:LKFT's Net Margin % is ranked better than 94.83% of 947
companies
in the Biotechnology industry
Industry Median: -89.56
vs WBO:LKFT: 46.83
Lakefront Biotherapeutics NV (WBO:LKFT) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Lakefront Biotherapeutics NV Net Margin % Related Terms
Lakefront Biotherapeutics NV Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:LKFT vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Lakefront Biotherapeutics NV's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lakefront Biotherapeutics NV Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lakefront Biotherapeutics NV's Net Margin % distribution charts can be found below:
* The bar in red indicates where Lakefront Biotherapeutics NV's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lakefront Biotherapeutics NV (WBO:LKFT) has a Net Margin % of 223.61% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Lakefront Biotherapeutics NV and its competitors. This is 5895% above median its historical median of 3.73. According to the industry distribution chart, Lakefront Biotherapeutics NV ranks #49 out of 947 companies in the Biotechnology industry, placing it in the top 5.2%.
Is Lakefront Biotherapeutics NV's Net Margin % too high?
Lakefront Biotherapeutics NV's current Net Margin % of 223.61% is 5895% above median its 10-year median of 3.73. Based on the distribution chart, Lakefront Biotherapeutics NV ranks #49 out of 947 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lakefront Biotherapeutics NV has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lakefront Biotherapeutics NV's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lakefront Biotherapeutics NV ranks #49 out of 947 companies for Net Margin %. This places Lakefront Biotherapeutics NV in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Lakefront Biotherapeutics NV and its competitors. Lakefront Biotherapeutics NV's current Net Margin % is 223.61%, which is 5895% above median its own 10-year median of 3.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakefront Biotherapeutics NV stock overvalued right now?
Based on GuruFocus' analysis, Lakefront Biotherapeutics NV (WBO:LKFT) is currently considered Possible Value Trap. The stock's GF Value™ is €104.25, compared to a current price of €25.50 — trading 75.5% below its estimated fair value. The current Net Margin % is 223.61%, which is 5895% above median its 10-year median of 3.73. Lakefront Biotherapeutics NV's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Lakefront Biotherapeutics NV (WBO:LKFT), the current Net Margin % is 223.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lakefront Biotherapeutics NV (WBO:LKFT) Overvalued in 2026?
Based on GuruFocus' analysis, Lakefront Biotherapeutics NV stock appears to be undervalued.
The current stock price of €25.50 is trading 75.5% below its estimated GF Value™ of €104.25.
GuruFocus considers Lakefront Biotherapeutics NV to be Possible Value Trap.
Key valuation signals for WBO:LKFT:
Net Margin %: 223.61% (5895% above median its 10-year median of 3.73)
GF Value™: €104.25 vs. price of €25.50 (75.5% below fair value)
No single metric tells the full story. See the WBO:LKFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
60GF Score
Get the complete analysis for WBO:LKFT
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:LKFT has been successfully added to your 
